Deadliest Cancer Stunned By Daily Pill

A once-daily pill called daraxonrasib just took one of the deadliest cancers in America and, for a specific group of patients, nearly doubled how long they lived.

Story Snapshot

A phase 3 trial found median survival of 13.2 months on daraxonrasib versus 6.7 months on chemotherapy in certain metastatic pancreatic cancer patients ^[2].
The drug targets RAS mutations, present in the vast majority of pancreatic adenocarcinomas, and is taken as a pill, not an infusion ^[2].
Daraxonrasib is not yet approved, but an expanded access pathway is already open at select centers ^[2].
Media headlines blur the nuance: the “doubling” applies to previously treated metastatic disease, not every pancreatic cancer patient ^[1]^[3].

A brutal cancer meets a focused new weapon

Pancreatic cancer has long been the diagnosis doctors quietly dread to deliver and patients barely have time to process. Most cases are discovered late, after the tumor has already spread, and the usual chemotherapy regimens buy months, not years.

That backdrop is why a new trial of daraxonrasib, a targeted pill from Revolution Medicines, created such a stir when data showed survival times jumping from 6.7 to 13.2 months in a key group of patients ^[2].

The trial, called RASolute 302, enrolled people whose pancreatic cancer had already spread and who had failed prior treatment, a group where expectations are usually modest at best ^[1]^[2].

These patients were randomly assigned to either daraxonrasib or the oncologist’s choice of standard chemotherapy.

Those on chemotherapy lived a median of 6.7 months, which aligns with the grim norm; those on daraxonrasib reached 13.2 months, with a hazard ratio of about 0.40, meaning a roughly 60 percent reduction in the risk of death during the study period ^[2].

New pill that doubles pancreatic cancer survival is ‘biggest leap in decades’ for deadly disease https://t.co/SW2ZmY1pVT

— The Sun (@TheSun) May 31, 2026

What “nearly doubles survival” really means

Television teasers and headlines saying a new drug “nearly doubles survival” sound as if someone cured pancreatic cancer. That is not what happened.

The improvement applies to previously treated metastatic pancreatic ductal adenocarcinoma, not to every patient with a new diagnosis, not to early-stage disease, and not yet to first-line treatment ^[1]^[2]^[3].

The study compared daraxonrasib to the best chemotherapy doctors would ordinarily pick in that second-line setting, and the pill clearly won on survival and tumor control in that lane ^[2].

That nuance matters for anyone trying to make decisions based on the news. The pill targets tumors with RAS mutations, particularly KRAS, which appear in more than 90 percent of pancreatic adenocarcinomas ^[2]. That makes the potential reach broad, but not universal.

Early data in distinct RAS-mutated subgroups showed objective response rates of around 30 to 35% and median overall survival in the 13 to 15-month range, confirming that this is real biological activity, not hype. The benefit is meaningful, yet still within the harsh reality that most patients ultimately die of the disease.

Pill instead of pump, and side effects that shift the tradeoffs

Beyond survival, quality of life makes or breaks a cancer treatment. Many standard regimens for metastatic pancreatic cancer require hours in an infusion chair, multiple drugs, and side effects that flatten patients. Daraxonrasib is a once-daily oral pill ^[2].

Prior and phase 3 data show that the most common problems are rash and mouth sores, followed by diarrhea, nausea, and vomiting ^[2].

Serious treatment-related events occurred in about a third of patients in earlier reports, but discontinuation rates for daraxonrasib in the phase 3 trial were around 1 percent, compared with roughly 11 percent on chemotherapy ^[2].

The world’s top cancer conference is wrapping up in Chicago today.

Daraxonrasib — a new targeted pill — nearly doubled survival for patients with advanced pancreatic cancer in a Phase 3 trial.

Results: 13.2 months median survival vs 6.7 months with chemotherapy, and fewer side… pic.twitter.com/pJeZx0AXM7

— Vitamvivere (@Vitamvivere) June 2, 2026

Patients on daraxonrasib reported slower worsening of cancer-related pain and overall quality of life compared with those on chemotherapy, according to company and advocacy-group summaries of the trial ^[2].

That means more of the extra months gained are likely to be months people can still function, interact with family, and make choices, not just time spent in medical limbo.

Regulators, access, and the caution behind the hope

The United States Food and Drug Administration has not yet approved daraxonrasib, but regulators have clearly noticed. The drug has been selected for a commissioner’s National Priority Voucher pilot program aimed at speeding review of treatments that address major health needs ^[2].

An expanded access program now allows some adults with previously treated metastatic pancreatic adenocarcinoma, who lack a comparable alternative and cannot join a trial, to receive the drug through participating centers ^[2]. That is an unusual level of early access for an unapproved therapy.

Still, the evidence so far comes from a company-sponsored phase 3 trial and earlier-phase studies, and the most detailed numbers are still filtered through conference presentations, advocacy writeups, and news releases ^[1]^[2]^[3]. Experience in oncology teaches that early, stunning results sometimes shrink when more data and broader patient populations come in.

The responsible takeaway is that daraxonrasib looks like a major new option for a clearly defined slice of pancreatic cancer patients, with survival and quality-of-life gains that line up with the numbers, not media wishful thinking. Patients and families should ask whether they fit that slice—and insist on the precise details, not just the headline.